Fontem Ventures welcomes Penn State report’s ‘fascinating contribution’ to debate on EVPS

Fontem Ventures, Britain’s leading e-cigarette company, has welcomed a report by Penn State College of Medicine

LONDON, December 10 2014 – Fontem Ventures, Britain’s leading e-cigarette company, has welcomed a report by Penn State College of Medicine whose research seemed to indicate that electronic vaping products (EVPs) are far less addictive than tobacco cigarettes.

More than 3,500 EVP users who had previously used tobacco products undertook the Penn State Cigarette Dependence Index and the Penn State Electronic Cigarette Dependence Index surveys whose questions assessed user dependence on each product.

Marc Michelsen, Fontem Ventures Director Communications & Public Affairs said: “Fontem Ventures welcomes the report published by Penn State College of Medicine which adds an interesting twist to the current debate on EVPs. Our research shows that more and more current and ex-smokers are increasing their use of EVPs for a variety of reasons, which includes wanting to reduce their exposure to tobacco.  This is further confirmation that the EVP category is an attractive lifestyle choice for those users of traditional tobacco who are looking for an alternative.

“Electronic Vaping Products should not being targeted at non-smokers or young people and our own Marketing Standard is already leading in this regard – as well as no flavours or packaging obviously directed to children.
However, Fontem Ventures questioned certain assumptions in the report, for example claims about EVPs acting as a gateway to tobacco smoking products.

A recent study from the UK’s Office of National Statistics suggests that the concern EVPs are a gateway to smoking are totally unfounded.

This confirms the view of Action on Smoking and Health (ASH), who in September of this released a report, analysed by Public Health England, which actually found that most young people (91%) have never tried an EVP and that only 2% of children who have not used tobacco have ever tried an EVP.

Marc Michelsen added: “Fontem Ventures agree with ASH director of policy Hazel Cheeseman’s comments in the Nursing Times that there is absolutely no evidence that young people who try EVPs move onto tobacco-based products.”

Fontem Ventures’ first UK product, Puritane® is on sale at Boots the Chemist and there are an estimated 1.5 million people in the UK using EVPs.

Other News

There are currently no more articles to view.